SCHEMBL18852325

SCHEMBL18852325

C=P(C)(C)CCC1OC(n2cnc3c(N)ccnc32)[C@H](I)[C@@H]1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 3/20 0.48
▸ ADORA2B P29275 3/20 0.48
▸ DNMT1 P26358 1/20 0.46
▸ DNMT3B Q9UBC3 1/20 0.46
▸ AHCY P23526 2/20 0.42
▸ EHMT1 Q9H9B1 1/20 0.41
▸ AMD1 P17707 1/20 0.40
▸ ADORA3 P0DMS8 3/20 0.39
▸ DPP4 P27487 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ SLC28A1 O00337 1/20 0.39
▸ MAP3K7 O43318 1/20 0.39
▸ SLC28A2 O43868 1/20 0.39
▸ GAPDH P04406 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ ADORA1 P30542 1/20 0.39
▸ STAT6 P42226 1/20 0.39
▸ PI4KA P42356 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14928581 1.00 ADORA2A (0.48) ADORA2AADORA2BDNMT1DNMT3BAHCY
SCHEMBL14946112 1.00 ADORA2A (0.48) ADORA2AADORA2BDNMT1DNMT3BAHCY
SCHEMBL15868482 1.00 ADORA2A (0.48) ADORA2AADORA2BDNMT1DNMT3BAHCY
SCHEMBL17231357 0.91 ADORA2A (0.55) ADORA2AADORA2BDNMT1DNMT3BAHCY
SCHEMBL18852382 0.89 ADORA2A (0.48) ADORA2AADORA2BDNMT1DNMT3BAHCY
SCHEMBL15868481 0.89 ADORA2A (0.48) ADORA2AADORA2BDNMT1DNMT3BAHCY
SCHEMBL14946122 0.89 ADORA2A (0.48) ADORA2AADORA2BDNMT1DNMT3BAHCY
SCHEMBL14946102 0.89 ADORA2A (0.48) ADORA2AADORA2BDNMT1DNMT3BAHCY
SCHEMBL14928482 0.89 ADORA2A (0.48) ADORA2AADORA2BDNMT1DNMT3BAHCY
SCHEMBL18852381 0.89 ADORA2A (0.48) ADORA2AADORA2BDNMT1DNMT3BAHCY

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170136132-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2017-05-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170136132-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, RNGTT, NSUN3 ADORA2A 399/4885ADORA2B 409/4885DNMT1 192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback